spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Novartis Pharma AG 

 HSMN NewsFeed - 15 Mar 2018
Ionis and Akcea Partner to Commercialize Inotersen for hATTR
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 Mar 2017
George Bickerstaff Elected to Inovio’s Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Sep 2016
BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 May 2016
Bicycle Therapeutics Strengthens Product Development Capabilities with Key Leadership Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Apr 2016
Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 12 Oct 2015
Abbott Announces Positive Clinical Results of Absorb(TM), the Naturally Dissolving Heart Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 19 May 2015
Abbott Announces CE Mark for New Advancement of Absorb Stent System for People with Heart Disease
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 5 Aug 2014
Alzheon Appoints Renowned Industry Leader, Jean-Pierre Sommadossi, PhD, to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 7 Apr 2014
Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Enter Into Definitive Merger Agreement Under Which Mallinckrodt Will Acquire Questcor For Approximately $5.6 Billion, Creating A Diversified, High-Growth Specialty Pharmaceuticals Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Oct 2013
FDA Files Genentech’s Supplemental Biologics License Application of Xolair(R) (omalizumab) for Chronic Idiopathic Urticaria (CIU)
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 10 Jul 2013
Abbott Announces Approval of Next-Generation XIENCE Xpedition(TM) Drug Eluting Stent System in Japan
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 11 Jun 2013
Questcor Pharmaceuticals Acquires Rights to Synacthen(R)
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 21 May 2013
Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 29 Apr 2013
Teva Expands Management Team with Appointment of Paul J. Sekhri as Group Executive Vice President, Global Business Development and Chief Strategy Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2013
Abbott Initiates Clinical Trial of Absorb(TM) in the United States
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Oct 2012
XDx Appoints Peter Maag as President and CEO
Diagnostics Personnel
 HSMN NewsFeed - 25 Sep 2012
Abbott Announces International Launch of the Absorb(TM) Bioresorbable Vascular Scaffold
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Sep 2012
QLT Announces Sale of Visudyne(R) to Valeant Pharmaceuticals
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 20 Aug 2012
Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 31 Jul 2012
Idenix Pharmaceuticals Announces Restructuring of Development and Commercialization Collaboration With Novartis Pharma AG
Biopharmaceuticals
 HSMN NewsFeed - 26 Jul 2012
Endocyte Appoints David Meek to Newly Created Position of Chief Commercial Officer
Biopharmaceuticals Personalized Medicine Personnel
 HSMN NewsFeed - 5 Jun 2012
Kinex Pharmaceuticals Appoints Dr. Jean-Pierre Sommadossi to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 May 2012
Elixir Medical Announces Excellent Results from DESolve I First-In-Man Study for the Fully Bioresorbable Drug Eluting Coronary Scaffold System
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2012
Abbott's XIENCE PRIME(TM) and XIENCE V(R) Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 3 May 2012
Creabilis Appoints Dr Simon Russell as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Apr 2012
Abbott Receives Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in Japan
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 22 Dec 2011
Abbott Initiates Clinical Trial to Study Drug Eluting Bioresorbable Therapy for Treatment of Peripheral Artery Disease
Devices Interventional
 HSMN NewsFeed - 8 Dec 2011
Abbott Initiates Clinical Trial to Evaluate the Absorb(TM) Bioresorbable Vascular Scaffold Compared to a Metallic Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Nov 2011
Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 8 Sep 2011
Abbott Initiates International ABSORB BTK Clinical Trial for Treatment of Below-the-Knee Critical Limb Ischemia
Devices
 HSMN NewsFeed - 23 May 2011
Elixir Medical Receives CE Mark for DESyne(TM) Novolimus Eluting Coronary Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 12 Apr 2011
Portola Pharmaceuticals Appoints Dr. James Topper to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Apr 2011
Novartis Therapy Gilenya Reduced the Risk of MS Disability Progression Regardless of Treatment History or Disease Severity, New Analysis Shows
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Jan 2011
Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 17 Dec 2010
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet (Pirfenidone) in Europe
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Nov 2010
Bausch & Lomb Names Charl van Zyl as Commercial Leader, Europe, Middle East and Africa
Devices Ophthalmology Personnel
 HSMN NewsFeed - 2 Nov 2010
Unigene Names Alex Martin VP Business Development and Head of Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Sep 2010
Abbott's XIENCE V(R) Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Sep 2010
Abbott's XIENCE V(R) Shows Outstanding Two-Year Clinical Results Versus TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Sep 2010
Portola Pharmaceuticals Appoints Jean-Jacques Bienaime to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Sep 2010
Abbott's Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Sep 2010
Novartis gains FDA approval for Gilenya, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 17 Sep 2010
Elixir Medical Corporation Initiates Enrollment in the EXCELLA BD Randomized Clinical Trial of the Elixir Novolimus Eluting Coronary Stent System with Bioabsorbable Polymer
Devices Interventional Cardiology
 HSMN NewsFeed - 8 Sep 2010
XDx Appoints New Vice President of Corporate Development and Legal Affairs
Diagnostics Personnel
 HSMN NewsFeed - 23 Jul 2010
Emisphere Provides an Update on Osteoarthritis Phase III Study With Oral Calcitonin
Biopharmaceuticals
 HSMN NewsFeed - 25 May 2010
Abbott's Groundbreaking Bioresorbable Technology Continues to Demonstrate Exceptional Clinical Results
Devices Interventional Cardiology
 HSMN NewsFeed - 6 May 2010
The New England Journal of Medicine Publication of SPIRIT IV Trial Results Confirm Superior Safety and Efficacy of Abbott's XIENCE V(R) Drug Eluting Stent Compared to TAXUS
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Feb 2010
FDA Acknowledges Need for Daily Multiple Sclerosis Pill by Granting Fingolimod Priority Review Status
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 9 Dec 2009
6-month results from EVEREST study evaluating Visudyne(R) therapy in patients with polypoidal choroidal vasculopathy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 19 Oct 2009
QLT restructures Visudyne(R) agreement
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 12 Oct 2009
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Oct 2009
Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 23 Sep 2009
Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 14 Sep 2009
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 31 Aug 2009
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Aug 2009
Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 13 Aug 2009
Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 21 Jul 2009
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jun 2009
Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 16 Jun 2009
Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
Devices Interventional Cardiology
 HSMN NewsFeed - 15 Jun 2009
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Jun 2009
FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2009
Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study
Devices Interventional Cardiology
 HSMN NewsFeed - 14 May 2009
Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval to Proceed With Phase 3 Development of Onalta(TM)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Apr 2009
Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease
Devices Interventional
 HSMN NewsFeed - 24 Mar 2009
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Mar 2009
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Mar 2009
Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Jan 2009
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Jan 2009
Valeant Pharmaceuticals Appoints Chief Operating Officer of Specialty Pharmaceuticals
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 17 Dec 2008
Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Oct 2008
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Oct 2008
New Data Shows Abbott's Bioabsorbable Drug Eluting Stent is Absorbed Within Two Years - Leaving Behind Functioning Blood Vessels
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Oct 2008
Elixir Medical Corporation Licenses Myolimus(TM) From Novartis Pharma AG for Site-Specific Drug Delivery Applications
Devices Drug Delivery Licensing Interventional Cardiology
 HSMN NewsFeed - 8 Jul 2008
Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day
Biopharmaceuticals
 HSMN NewsFeed - 3 Jul 2008
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 5 Jun 2008
FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 May 2008
Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Jan 2008
Dr. Reddy's Announces Settlement of Exelon(R) (rivastigmine tartrate) ANDA Litigation With Novartis
Biopharmaceuticals Generics Neurology Litigation
 HSMN NewsFeed - 4 Jan 2008
Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2007
Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 3 Dec 2007
APT Pharmaceuticals Adds Paul Sekhri to Board of Directors
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 28 Sep 2007
Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2007
First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Biopharmaceuticals
 HSMN NewsFeed - 18 Aug 2007
Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Aug 2007
FDA Grants Additional Six Months Marketing Exclusivity for the High Blood Pressure Medicine Diovan(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Jul 2007
Medarex Announces Initiation by Licensing Partner of Phase III Clinical Trial for Muckle Wells Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 13 Jul 2007
Valopicitabine Development Program Placed on Clinical Hold in the United States
Biopharmaceuticals
 HSMN NewsFeed - 21 Jun 2007
Exforge(R) Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jun 2007
APT Acquires Exclusive Worldwide Rights to Develop and Commercialize Inhalable Cyclosporine to Prevent Lung Transplant Rejection
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 21 May 2007
Intercept Pharmaceuticals Expands Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 May 2007
Single-Tablet Combination of Tekturna(R) and Diuretic, an Important New Option for People With High Blood Pressure, Accepted for Review in U.S.
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 May 2007
Once-yearly Reclast(R) Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis
Biopharmaceuticals Orthopaedic
 HSMN NewsFeed - 30 Apr 2007
Sebivo(R) (Telbivudine) Approved in European Union as a New Treatment for Chronic Hepatitis B Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Apr 2007
Reclast(R) Receives US Approval as a Highly Effective Treatment for Patients with Paget's Disease of the Bone
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Mar 2007
Tekturna(R), First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Mar 2007
Idenix Pharmaceuticals, Inc. Announces Resignation of Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Mar 2007
Tekturna(R) - The First New Type of High Blood Pressure Medicine In More Than a Decade - Receives Its First Approval in the US
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 2 Mar 2007
SEBIVO(R) (Telbivudine) Approved in China as New Treatment Option for Patients with Chronic Hepatitis B
Biopharmacetuicals Regulatory
 HSMN NewsFeed - 27 Feb 2007
Initiation of Phase III Program Using Emisphere's eligen(R) Technology for Oral Salmon Calcitonin
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 23 Feb 2007
SEBIVO(R) (telbivudine) Recommended for Approval in European Union as a new Treatment for Patients with Chronic Hepatitis B
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Jan 2007
Molecular Insight Pharmaceuticals, Inc. Acquires Clinical Stage, Targeted Radiotherapeutic Candidate Onalta(TM) (Formerly OctreoTher(TM))
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 8 Jan 2007
Idenix Pharmaceuticals, Inc. Announces Appointment of Douglas Mayers, M.D. as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2007
ProEthic Pharmaceuticals Announces Positive Phase III Clinical Trial Results for Fast-Acting Migraine Product Candidate
Biopharmaceuticals
 HSMN NewsFeed - 22 Dec 2006
Exforge(R) Receives US Regulatory Approval as a New and Highly Effective Treatment Option for Patients with High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Dec 2006
Norman C. Payson, M.D., Elected to Board of Directors of Idenix Pharmaceuticals
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2006
New Evidence Reinforces Efficacy and Tolerability of Galvus(R) as a New Once-Daily Oral Treatment Option for Patients With Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 20 Nov 2006
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP)
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 9 Nov 2006
Genentech Announces Agreement to Acquire Tanox for $20 Per Share
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Oct 2006
Idenix Announces New 24-Week Data From A Phase IIb Clinical Trial Of Valopicitabine Plus Pegylated Interferon in Treatment Naive Genotype-1 Hepatitis C Patients
Biopharmaceuticals
 HSMN NewsFeed - 25 Oct 2006
TYZEKA(TM) (telbivudine) Approved by U.S. Food and Drug Administration (FDA) as a New Treatment for Patients with Chronic Hepatitis B
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Oct 2006
New Data for Zelnorm(R) Demonstrate Relief of Multiple Symptoms of Dysmotility-Type Dyspepsia
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 11 Oct 2006
Novartis Launches 'GALIANT' Study Comparing the Investigational Drug Galvus(R) and a Leading Class of Oral Anti-Diabetic Medicines
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 21 Sep 2006
Telbivudine Approved in Switzerland for Chronic Hepatitis B
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Sep 2006
Once-Yearly Reclast(R)* Demonstrates Highly Significant Fracture Risk Reductions in the Treatment of Postmenopausal Osteoporosis, New Study Shows
Biopharmaceuticals
 HSMN NewsFeed - 19 Jul 2006
Exelon(R) Patch, the first transdermal therapy for Alzheimer's disease, may provide a promising new approach to treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 May 2006
Conor Medsystems Announces First Patient Treated with Dual-Drug Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 17 May 2006
Novartis Announces Efficacy Data on New Investigational High Blood Pressure Therapies at The American Society of Hypertension Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 11 May 2006
Conor Medsystems Initiates RAPID Clinical Study for First Pimecrolimus Drug-Eluting Stent
Devices Interventional Cardiology
Return to NewsFeed  

 Additional items found! 135

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 135 additional stories matching:
Novartis Pharma AG
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.